El interés en corto de Viridian Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Viridian Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Viridian Therapeutics (NASDAQ:VRDN) Bolsa, Informe de interés en corto

VIRIDIAN THERAPEUTICS INC

Viridian Therapeutics

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics Inc

Trading Ideas

SXTP

60 Degrees Pharmaceuticals Shares Halted On Circuit Breaker To The Downside, Stock Now Down -4.81%

Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has outperformed the market over the past 5 years by 10.19% on an annualized basis producing an average annual return of 23.45%. Currently, Meta Platforms has a market capitalization of $1.73 trillion. 
Buying $1000 In META: If an investor had bought $1000 of META stock 5 years ago, it would be worth $2,956.81 today based on a price of $684.23 for META at the time of writing.
<h3>Meta Platforms's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749048341_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

MULN

Mullen Automotive Shares Halted On Circuit Breaker To The Upside, Stock Now Up 116.3%

Activity in the U.S. services sector—long the backbone of the economy—unexpectedly showed no signs of growth in May, while cost pressures surged to their highest level in over three years, intensifying fears that tariffs and trade frictions are <a href="https://www.benzinga.com/news/econ-s">stoking a stagflationary environment.</a>
The Institute for Supply Management's Services Purchasing Managers Index fell to 49.9% in May, down from 51.6% in April, missing consensus expectations of 52%. The reading marked the first marginal contraction in services activity since June 2024. The ISM Services PMI&nbsp;has contracted in only four of the last 60 months dating back to June 2020.
New orders plunged to 46.4%, a 5.9 percentage point drop on the month, while business activity stagnated at 50%, down sharply from April's 53.7%. 
Employment improved slightly to 50.7%, after two months in contraction territory. The Backlog of Orders Index sank to 43.4%, its lowest since August 2023, while inventories contracted again, with the index falling to 49.7%.
&#8220;May's PMI&nbsp;level is not indicative of a severe contraction, but rather uncertainty that is being expressed broadly among ISM Services Business Survey panelists,&#8221; said Steve Miller, chair of the Institute for Supply Management.
&#8220;Respondents continued to report difficulty in forecasting and planning due to longer-term tariff uncertainty and frequently cited efforts to delay or minimize ordering until impacts become clearer," he said.
<h3 class="wp-block-heading">Heavy Price Pressures Hit Services Activity</h3>
The standout figure was the Price Index, which jumped to 68.7%, up 3.6 percentage points from April and the highest level since November 2022. Prices have surged 7.8 points in just two months, an acceleration not seen since late 2022.
&#8220;Tariff impacts are likely elevating prices paid by services sector companies, with the Prices Index hitting its highest level since November 2022, when the Bureau of Labor Statistics' CPI indicated that prices had increased 7.1 percent as compared to November 2021,&#8221; Miller added.
<h3 class="wp-block-heading">Market Reactions: Treasury Yields Hit 1-Month Low</h3>
Wall Street pared early morning gains after the data, with the S&amp;P 500 – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – trading flat for the day. 
The U.S. dollar lost further ground, extending losses suffered earlier in the day after a weaker-than-expected employment growth in May. 
The Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>) – which tracks the U.S. dollar index (DXY) – fell 0.5% for the session. 
Investors flocked to Treasuries amid rising growth concerns. Yields on 10-year Treasury bonds tumbled to 4.37%, hitting the lowest levels since May 9. The yield on the 30-year Treasury bond fell 8 basis points to 4.90%. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/06/45768817/us-private-sector-hiring-slows-the-most-in-2-years-powell-must-now-lower-the-rate-trump-says">US Private Sector Hiring Slows The Most In 2 Years: &#8216;Powell Must Now Lower The Rate,&#8217; Trump Says </a></li>
</ul>
Photo: Shutterstock

Macro Economic Events

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

PowerShares DB US Dollar Index Bullish Fund

Services Activity Slips Into Stagnation In May As Cost Pressures Surge To November 2022 Highs

Genesco Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCO#NYSE">GCO</a>), on Wednesday, reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45766387/genesco-inc-reports-fiscal-2026-first-quarter-results" rel="noreferrer noopener">mixed first-quarter 2026 results</a> and reaffirmed fiscal 2026 EPS guidance.
The company reported an adjusted loss per share of $2.05, missing the street view of $2.00 loss. Quarterly sales of $473.973 million (increased 4% year over year) were above the analyst consensus estimate of $465.30 million.
Net sales were driven by a 5% increase at Journeys, 4% at Schuh, and 7% at Genesco Brands, partly offset by a 3% decline at Johnston &amp; Murphy.
Also Read:<a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45770679/alibaba-jd-see-sales-soar-in-618-festival-apple-and-xiaomi-emerge-as-top-selling-brands" rel="noreferrer noopener"> Alibaba, JD See Sales Soar In 618 Festival, Apple And Xiaomi Emerge As Top Selling Brands</a>
Comparable sales rose 5%, with stores up 5% and e-commerce up 7%. On a constant currency basis, Schuh sales rose 1%.
The first quarter&#8217;s gross margin fell to 46.7% from 47.6% a year ago, mainly due to brand mix shifts at Journeys and Schuh, promotions at Schuh, and lower margins from product liquidations at Genesco Brands.
Genesco reported a GAAP operating loss of $28.1 million, or 5.9% of sales, down from $32.1 million, or 7%, a year ago. On an adjusted basis, the loss narrowed to $27.9 million from $30.0 million, with the operating margin improving to a loss of 5.9% of sales from a loss of 6.5% in the first quarter last year.
As of May 3, 2025, Genesco held $21.7 million in cash, up from $19.2 million a year earlier. Total debt rose to $121 million from $59.4 million, mainly due to a 15% inventory increase to support higher demand at Journeys.
Genesco repurchased 604,531 shares for $12.6 million, or $20.79 per share, during the quarter. Under its expanded buyback program, announced in June 2023, it has $29.8 million remaining.
In the first quarter, capital expenditures totaled $19 million, mainly for retail stores and other projects. The company opened four new stores and closed 26, ending the quarter with 1,256 stores. This represents a 5% decrease from 1,321 stores at the end of the first quarter last year. Overall square footage also decreased by 3% year-over-year.
Mimi E. Vaughn, Genesco&#8217;s Board Chair, president, and CEO, said, &#8220;While an already choppy consumer environment has become more pronounced recently from the increased uncertainty due to tariffs, our diversified sourcing and mitigation actions position us well to manage the current tariff impact. In addition, our strong strategic positioning and track record of evolving our businesses in the face of market disruptions are giving us confidence in successfully navigating the current environment.&#8221;
&#8220;Today, we are reiterating our full-year adjusted EPS guidance of $1.30 to $1.70, incorporating the impact of current tariffs. Although there is ongoing external market uncertainty, we know our businesses are strong, and we are making investments in product, stores, and marketing across all brands to drive growth,&#8221; commented Sandra Harris, Genesco&#8217;s Senior VP of Finance and CFO.
For fiscal 2026, Genesco reaffirmed its expectation of adjusted diluted EPS between $1.30 and $1.70 versus the consensus estimate of $1.47, factoring in current tariffs.
Total sales are now projected to rise 1%–2%, up from prior guidance of flat to 1%, due to favorable foreign exchange. Comparable sales range outlook narrowed to up 2% to 3% versus the prior range of up 2% to 4%, with no additional share buybacks assumed and a 29% tax rate.
Price Action: GCO shares are trading higher by 1.39% to $22.66 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45768682/dollar-tree-q1-same-store-sales-jump-5-4-warns-of-near-term-profit-drop-on-tariff-pressure-transition-costs" target="_blank" rel="noreferrer noopener">Dollar Tree Q1 Same-Store Sales Jump 5.4%, Warns Of Near-Term Profit Drop On Tariff Pressure, Transition Costs</a></li>
</ul>
Photo by JHVEPhoto via Shutterstock

Earnings

Guidance

Movers

Genesco Acknowledges 'More Pronounced' Tariff Impact, Stands By Guidance

Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) volatility is well known, but Bitwise Chief Investment Officer Matt Hougan argues that when viewed within the context of a broader portfolio, the asset may improve performance without <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42170334/bitcoin-investor-turns-daily-30-purchases-into-1-million-portfolio-in-7-years-10-months-and-12-days">proportionately increasing risk</a>.
In a note <a href="https://experts.bitwiseinvestments.com/cio-memos/more-return-with-less-risk">published</a> by Bitwise Asset Management on June 3, Hougan questions the conventional practice of evaluating Bitcoin in isolation.
"When you think about adding Bitcoin to a portfolio, don't do it in isolation. Think about it in the context of your entire risk budget," he wrote.
Hougan examined several hypothetical portfolio allocations from 2017 to 2024, comparing traditional 60/40 stock-bond splits with variations that include Bitcoin. 
While a 5% allocation to Bitcoin significantly increased returns, from 107% to 207%, the overall portfolio volatility, measured by standard deviation, increased only modestly from 11.3% to 12.5%.
This risk-return profile, Hougan said, shows that "adding Bitcoin to portfolios has historically boosted returns without significantly increasing risk," citing Bitcoin&#8217;s low correlation to both equities and fixed income.
But Hougan proposes that a more effective method may involve adjusting other portfolio components to compensate for Bitcoin's risk. 
In one model, Hougan explores a portfolio that adds 5% Bitcoin while simultaneously increasing bond exposure and tilting it toward short-duration Treasuries. 
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45767539/anthony-scaramucci-says-sam-bankman-frieds-25-year-sentence-is-too-steep">Anthony Scaramucci Says Sam Bankman-Fried&#8217;s 25-Year Sentence Is &#8216;Too Steep&#8217;</a>
This combination, referred to as Portfolio 3, outperformed the traditional allocation and even matched the return of the Bitcoin-enhanced portfolio, with lower risk.
The analysis goes further with a Portfolio 4, which drops equity exposure to 40%, increases bonds to 50%, and allocates 10% to Bitcoin. 
This configuration delivered higher returns with less volatility than portfolios with more equity risk and less crypto exposure.
"Portfolio 3 generated higher returns than Portfolio 1 and roughly the same returns as Portfolio 2 with less risk than either," Hougan noted. 
The suggestion is not prescriptive, but rather a prompt for investors to rethink how they fit Bitcoin within their broader financial strategy.
Hougan acknowledged the outsized returns of Bitcoin in earlier years may not repeat, cautioning, "Of course, there's no guarantee this will persist in the future." However, he insists that rethinking the allocation method is critical: "It makes you wonder: What if you push this further?"
The analysis is rooted in data from Bloomberg, covering a range of traditional and crypto assets from January 2017 through December 2024, and does not account for taxes or transaction fees. 
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45757170/trump-branded-crypto-wallet-sparks-controversy-trump-family-denies-involvement">Trump-Branded Crypto Wallet Sparks Controversy, Trump Family Denies Involvement</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Can Bitcoin Boost Portfolio Returns Without Increasing Risk? Bitwise's Matt Hougan Says It Can

Scotiabank analyst Robert Hope maintains Algonquin Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AQN#NYSE">AQN</a>) with a Sector Perform and raises the price target from $6 to $6.5.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Algonquin Power, Raises Price Target to $6.5

Crypto analyst <a href="https://www.benzinga.com/topic/benjamin-cowen">Benjamin Cowen</a> warns that Bitcoin&#8217;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) recent correction could deepen through Q3, pointing to familiar patterns in key technical indicators.
What Happened: In his June 4 <a href="https://www.youtube.com/watch?app=desktop&amp;v=Is7v_45oxoM&amp;feature=youtu.be&amp;ab_channel=BenjaminCowen">podcast</a>, Cowen noted that Bitcoin has dropped around 7–8% from all-time highs, nearing his forecasted 10–15% pullback following a golden cross. He <a href="https://www.youtube.com/watch?app=desktop&amp;v=Is7v_45oxoM&amp;feature=youtu.be&amp;ab_channel=BenjaminCowen">emphasized</a> that the "supply in profit" metric, currently at 96.71%, is flashing warning signs as previous market tops have occurred when this indicator exceeds 97–99%.
Cowen explained that historically, market pullbacks follow when profit-taking saturates the market. Notable peaks, including those in March 2024 and December 2024, coincided with this metric topping 97–98%.
When the supply in profit gets really well above 90%, you at least need to be on the lookout for a pullback, Cowen warned.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45757206/bitcoin-stalls-at-106000-whats-coming-next">Bitcoin Stalls At $106,000: What&#8217;s Coming Next?</a>
What's Next: Cowen <a href="https://www.youtube.com/watch?v=x4ptTIHciXI">sees</a> mid-June as a critical period. He flagged a recurring seasonal pattern where Bitcoin has shown weakness in Q3 for the past two years. If BTC fails to break higher soon, it's probably setting up for some Q3 weakness.
Cowen outlined two scenarios:
<ul class="wp-block-list">
<li>Bullish case: BTC holds the bull market support band as it did in 2023, allowing a continued uptrend.</li>
<li>Bearish case: A deeper correction toward the $60,000s, potentially signaling that the current cycle has peaked.</li>
</ul>
Despite near-term caution, Cowen remains more bullish on Bitcoin than altcoins, saying Bitcoin offers better upside-to-downside risk. He noted that altcoins tend to stand still when Bitcoin rallies.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/45767169/bitcoin-ethereum-xrp-dogecoin-tick-up-as-battle-for-105000-intensifies">Bitcoin, Ethereum, XRP, Dogecoin Tick Up As &#8216;Battle For $105,000&#8217; Intensifies</a></li>
</ul>
Photo: Shutterstock

Markets

Bitcoin's Post-Golden Cross Correction Playing Out — Benjamin Cowen Flags Signs Of Q3 Weakness

<a href="https://www.nytimes.com/2025/06/03/health/multiple-myeloma-car-t-immunotherapy.html" title="https://www.nytimes.com/2025/06/03/health/multiple-myeloma-car-t-immunotherapy.html">https://www.nytimes.com/2025/06/03/health/multiple-myeloma-car-t-immunotherapy.html</a>

Rumors

LEGN

Watching Legend Biotech; Traders Circulate NY Times Article Titled "From No Hope to a Potential Cure for a Deadly Blood Cancer", Users Compare The Co's CAR-T Therapy, CARVYKTI, Saying It Offers Hope Of Cure

ChargePoint Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is about to plug into the earnings grid, and Wall Street's biggest brains are already circling the EV charging play. The company reports <a href="https://www.benzinga.com/quote/CHPT/earnings">first quarter results</a> after the bell Wednesday, with expectations for a loss of 5 cents per share on $108.07 million in revenue.
But here's the twist: the stock is quietly mounting a comeback.
After shedding over 54% in the past year, ChargePoint has sprinted +33% over the last month, sparking serious interest from hedge fund royalty. Steve Cohen's Point72, Cliff Asness' AQR and Philippe Laffont's Coatue Management have all initiated new positions as of March, buying the dip at an average of around $0.84 &#8211; which is where the stock was trading on Wednesday.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45547600/whats-going-on-with-chargepoint-stock-today-3">What&#8217;s Going On With ChargePoint Stock On Wednesday?</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0604"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04062354/Screenshot-2025-06-04-at-3.53.37-PM.png" alt="" class="wp-image-937991" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04062354/Screenshot-2025-06-04-at-3.53.37-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/04062354/Screenshot-2025-06-04-at-3.53.37-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0604">Chart created Benzinga Pro</a>
Technically, CHPT stock is sending all the right short-term signals. The stock trades above its eight, 20, and 50-day simple moving averages (SMA), with the MACD (moving average convergence/divergence) indicator in positive territory and the RSI (relative strength index) climbing to 63.17, suggesting bullish momentum without yet entering the overbought territory.
Still, it's not all green lights. The longer-term 200-day average sits way up at $1.04, keeping some caution in play. But short-term traders are clearly charging up: the eight-day SMA bullish signal, rising volume, and sentiment reversal have made this penny EV stock a hot pre-earnings momentum play.
And when names like Cohen, Asness, and Laffont start nibbling at a company once left for dead — you know something's up.
Tonight's earnings could either recharge the rally or blow a fuse. For now, the big money is plugged in, and the CHPT stock chart is blinking bullish.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45164220/evgo-vs-chargepoint-tariffs-technicals-and-the-road-to-profitability">EVgo Vs. ChargePoint: Tariffs, Technicals, And The Road To Profitability</a></li>
</ul>
Photo: YuniqueB/Shutterstock

Hedge Funds

Technicals

Previews

Tech

CHPT

Cohen, Asness, Laffont Bet On ChargePoint - Will Q1 Earnings Spark A Breakout?

USA Gasoline Inventories 5.219M Barrel Build Vs 1.500M Barrel Build Est.; 2.441M Barrel Draw Prior

USA EIA Weekly Distillates Stocks 4.230M Barrel Build Vs 2.200M Barrel Build Est.; 0.724M Barrel Draw Prior

Macro Notification

General

USA Crude Oil Inventories 4.304M Barrel Draw Vs 2.900M Barrel Draw Est.; 2.795M Barrel Draw Prior

Crown Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>) has outperformed the market over the past 20 years by 1.64% on an annualized basis producing an average annual return of 9.97%. Currently, Crown Holdings has a market capitalization of $11.42 billion. 
Buying $1000 In CCK: If an investor had bought $1000 of CCK stock 20 years ago, it would be worth $6,677.67 today based on a price of $98.09 for CCK at the time of writing.
<h3>Crown Holdings's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749047412_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Crown Holdings 20 Years Ago Would Be Worth This Much Today

Agreement involves Natural Graphite Material; complements existing 2024 agreement covering Synthetic Anode Active Materials
Follows Graphite One's listing on U.S. Federal Fast-41 Permitting Dashboard and completion of its NI 43-101 compliant Feasibility Study funded by a $37.3 million Department of Defense award under the Defense Production Act
Graphite One CEO, Anthony Huston: "This Agreement makes Graphite One the only company to date to provide both natural and synthetic graphite materials required for battery anodes to a U.S. EV company."
VANCOUVER, BC, June 4, 2025 /PRNewswire/ - Graphite One Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/GPH#TSXV">GPH</a>)&nbsp;(OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GPHOF#OTCQX">GPHOF</a>) ("Graphite One", or the "Company"), is pleased to announce that as part of its plan to build a complete U.S. supply chain for advanced graphite materials, the Company has entered into a second non-binding supply agreement (the "Supply Agreement") for anode active materials ("AAM") with Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) ("Lucid"), maker of the world's most advanced electric vehicles.

Contracts

GPHOF

LCID

TSXV:GPH

Graphite One Signs Second Supply Agreement With Lucid Group For Natural Graphite Anode Materials; Deal Follows Completion Of $37.3M DOD-Funded Feasibility Study And Fast-41 Permitting Milestone

UBS analyst Joshua Spector maintains Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) with a Buy and lowers the price target from $10 to $8.5.

TROX

UBS Maintains Buy on Tronox Holdings, Lowers Price Target to $8.5

UBS analyst Michael Lasser maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Neutral and lowers the price target from $54 to $48.

UBS Maintains Neutral on Academy Sports, Lowers Price Target to $48

UBS analyst Rodrigo Alcantara maintains BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) with a Neutral and raises the price target from $32 to $33.

TBBB

UBS Maintains Neutral on BBB Foods, Raises Price Target to $33

WIIM

GTLS

Chart Industries shares are trading lower after the company announced a $19 billion merger with Flowserve.

UBS analyst Mauricio Serna maintains Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) with a Buy and raises the price target from $84 to $95.

UBS Maintains Buy on Signet Jewelers, Raises Price Target to $95

Press Releases

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)

Comments

Viridian Therapeutics

Interés en corto

Viridian Therapeutics (NASDAQ:VRDN) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL